Low Back PainNCT03705676
Unraveling Back Pain Chronicity: an EMG and EEG Study
A study testing Rapid Arm Movements, Unpleasant stimulus and Vibrotactile stimulus in people with Low Back Pain, run by University Ghent at 1 site in Belgium.
Trial summary
This study aims at examining the influence of both threat of experimentally induced pain and clinical low back pain (LBP) on trunk motor control on the one hand and brain activity related to movement preparation on the other hand. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Low Back Pain
- What is being tested?
- Rapid Arm Movements, Unpleasant stimulus and Vibrotactile stimulus
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 107 participants
- Where
- 1 siteBelgium
- Study dates
- 3 Mar 2017to 17 Apr 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adult subjects.
- People with non-specific recurrent LBP for at least 2 episodes last year. (1 episode = >24h complaints; 2 episodes are separated by a painfree period of at least 1 month)
- People with non-specific chronic LBP for at least 3 days a week and this for at least 3 months on a row.
Who cannot join
- People with a history of pain or current pain
- severe pathologies
- traumata
- cardiorespiratory disorders
- neurological disorders
- vestibular disorders
Show all 62Show fewer
- endocrinologic disorders
- psychiatric and cognitive disorders
- colour blindness
- sleeping disorders
- psychological disorders or major depressions
- major surgery to the spine or upper limbs
- clinically relevant malalignments and deformities
- malignancies
- substance abuse of alcohol or drugs
- consumption of analgesics without prescription 24 hours or with prescription two weeks before testing
- use of psychotropic medication
- extreme physical activities two days before testing
- professional athletes
- pregnant women or women < 1 year postnatally
- RLBP
- specific reason for LBP (e.g. herniation <2y, fracture, rheumatic disease,...)
- severe pathologies
- traumata
- cardiorespiratory disorders
- neurological disorders
- vestibular disorders
- endocrinologic disorders
- psychiatric and cognitive disorders
- colour blindness
- sleeping disorders
- psychological disorders or major depressions
- major surgery to the spine or upper limbs
- clinically relevant malalignments and deformities
- malignancies
- substance abuse of alcohol or drugs
- consumption of analgesics without prescription 24 hours or with prescription two weeks before testing
- use of psychotropic medication
- extreme physical activities two days before testing
- professional athletes
- pregnant women or women < 1 year postnatally
- CLBP
- specific reason for LBP (e.g. herniation <2y, fracture, rheumatic disease,...)
- severe pathologies
- traumata
- cardiorespiratory disorders
- neurological disorders
- vestibular disorders
- endocrinologic disorders
- psychiatric and cognitive disorders
- colour blindness
- sleeping disorders
- psychological disorders or major depressions
- major surgery to the spine or upper limbs
- clinically relevant malalignments and deformities
- malignancies
- substance abuse of alcohol or drugs
- consumption of analgesics without prescription 24 hours or with prescription two weeks before testing
- use of psychotropic medication
- extreme physical activities two days before testing
- professional athletes
- pregnant women or women < 1 year postnatally
Trial locations and contacts
1 site in 1 country.
Belgium1 site
Vakgroep REVAKI (Ghent University - Ghent University Hospital)
Ghent, 9000
About this study
Official title: Unraveling the Puzzle of Back Pain Chronicity: an Integrative Perspective on Sensorimotor Control and Maladaptive Cognitive Processes
This study aims at examining the influence of both threat of experimentally induced pain and clinical low back pain (LBP) on trunk motor control on the one hand and brain activity related to movement preparation on the other hand. Therefore, 3 groups are studied: healthy controls, people with recurrent LBP, and people with chronic LBP. A comparison in electromyography (EMG) of the trunk muscles and electroencephalography (EEG) activity between the 3 groups will be made in 2 conditions: a control condition without experimental pain on 1 test day, and a fear condition with experimental pain on another test day. In both conditions a motor control task will be performed and muscle and brain activity will be measured during each motor control task.
It is hypothesised that motor control will be different between the 3 groups in both conditions, i.e. delayed trunk muscle onset in LBP groups compared with controls. With regards to the brain activity, it is expected that preparation for movement will also be delayed in the LBP groups. Furthermore, it is expected that the fear condition will entail differences in both EMG and EEG within each group.
Read the detailed description
March 2017 - April 2018. 30 healthy participants, 30 recurrent and 30 chronic LBP patients all aged 18-45 and of both genders were tested for 2 conditions on 2 separate days, i.e. a control condition (C) on 1 test day; a fear (F) condition consisting out of threat (T) and no threat trials (NT) on another test day. The order of test days was randomized.
1 block of 240 rapid arm movements (RAM) with the dominant arm was performed per condition, while electroencephalography (EEG) of the brain and surface electromyography (sEMG) of the Internal Oblique/Transversus Abdominis, External Oblique, Multifidus and Iliocostalis Lumborum pars Thoracis muscles were measured bilaterally. sEMG of the Anterior Deltoid muscle of the dominant arm was also measured. This RAM was used to induce an internal perturbation to the postural balance of subjects and is an often used task in the study of trunk motor control. Midway the RAM block, the participants got a short intermission of 90 seconds seated rest. Both conditions consisted of a warning cue (colored dot on a screen) followed by a go cue (arrow indicating either an upwards or downwards rapid arm movement) or a no-go cue ('STOP') and 12 seconds rest before the next trial. Harmless vibrotactile stimuli were always administered to the low back region during the appearance of the warning cue. During the C, a white warning cue was presented (safe cue), meaning that the RAM would never be accompanied by a painful electrocutaneous stimulus in that condition. During the F a safe (no threat) or a threatening warning cue could be presented (50-50%); in 25% of the trials after the threatening cue an electrocutaneous stimulus was given to the lower back region; the trials after the no threat cue were never accompanied with painful stimuli.
The intensity of the electrocutaneous stimulus was self-determined by participants through a staircase paradigm and was administered by a digitimer system.
At the beginning of each test day several questionnaires were also administered to control for psychological factors and physical activity, i.e. Central Sensitization Index (CSI), Hospital Anxiety and Depression Scale (HADS), Tampa Scale for Kinesiophobia (TSK), Pain Catastrophizing Scale (PCS), Pain Vigilance and Awareness Questionnaire (PVAQ), Roland-Morris Disability Questionnaire (RMDQ), International Physical Activity Questionnaire (IPAQ) and a general questionnaire regarding socio-demographic information and history of complaints. Furthermore, complaint specific questionnaires were also administered, but only for the clinical populations (RLBP and CLBP)
Statistical analysis will be performed to assess whether and to what extent both threat and LBP might influence motor control as measured with EMG during RAM. Furthermore, the effect of both on cortical movement preparation and somatosensory processing will also be assessed based on the EEG measurements.
- Conditions
- Low Back Pain
- Being tested
- Rapid Arm Movements, Unpleasant stimulus, Vibrotactile stimulus
- Keywords
- Sensorimotor control, Event-related potentials, Cortical movement preparation
- Medical subject headings
- Low Back Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rapid Arm MovementsBehavioural
240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
Unpleasant stimulusDevice
Also called Electrocutaneous stimulus
An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
Vibrotactile stimulusDevice
In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
| Study group | Role | What they receive |
|---|---|---|
| Healthy controls - control condition | Active comparator | Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli. Receives: Behavioral: Rapid Arm Movements; Device: Vibrotactile stimulus |
| Healthy controls - fear condition | Experimental | Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials. Receives: Behavioral: Rapid Arm Movements; Device: Unpleasant stimulus; Device: Vibrotactile stimulus |
| RLBP - control condition | Active comparator | Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli. Receives: Behavioral: Rapid Arm Movements; Device: Vibrotactile stimulus |
| RLBP - fear condition | Experimental | Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials. Receives: Behavioral: Rapid Arm Movements; Device: Unpleasant stimulus; Device: Vibrotactile stimulus |
| CLBP - control condition | Active comparator | Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli. Receives: Behavioral: Rapid Arm Movements; Device: Vibrotactile stimulus |
| CLBP - fear condition | Experimental | Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials. Receives: Behavioral: Rapid Arm Movements; Device: Unpleasant stimulus; Device: Vibrotactile stimulus |
What is being measured
The primary outcome is the main question the study is designed to answer.
Trunk muscle EMG latency
Latency of the activation onset of the trunk muscles on EMG compared to prime mover onset (Anterior Deltoid) in milliseconds.
Measured: 2 hours
Contingent Negative Variation
A cortical EEG-potential that reflects movement preparation in the timeframe between a warning cue and a go cue in Volt.
Measured: 2 hours
Somatosensory Evoked Potentials
Cortical EEG-potentials that reflect the awareness and processing of somatosensory information, in this case vibrotactile stimuli on the lower back in Herz.
Measured: 2 hours
Secondary outcomes (11)
Visual Analogue Scale for Pain
A self-reported rating by participants for experienced low back pain, which was assessed at baseline, midway the RAM block (during the 90s intermission) and after the RAM. Participants had to indicate on a horizontal axis of 10 cm how much LBP they experienced at that moment with at the left side of the axis (0) 'no pain all' and on the right side of the axis (10) 'maximal/worst pain ever experienced'. The numeric score (0-10) was calculated by the researcher and was not visible for participants.
Measured: Before, midway and after each RAM block, with a duration of 10 seconds. This in both test day 1 and 2, which are minimally separated by 5 days between test days.
Rating of Perceived Exertion/Borg
A self-reported rating by participants for assessing how fatiguing the RAM was. This was assessed after the RAM task. This is a vertical scale ranging from 6 at the top (no exertion) to 20 at the bottom ('maximal exertion') of the scale. Participants saw both incremental numbers from 6-20 and descriptions at numbers 7 ('very very light'), 9 ('very light'), 11 ('reasonably light'), 13 ('quite heavy'), 15 ('heavy'), 17 ('very heavy'), 19 ('very very heavy'), 20 ('maximal exertion').
Measured: After each RAM block, with a duration of 5 seconds. This in both test day 1 and 2, which are minimally separated by 5 days between test days.
International Physical Activities Questionnaire
The IPAQ was administered before each test session to question participants about the physical activities they performed during the last 7 days. This in order to control for week-to-week differences in physical exertion levels and in order to compare physical activity between subjects. Based on these scores 3 levels of physical activity could be determined with level 1 (low), 2 (moderate) and 3 (high) physical activity. These levels are calculated based on the amount of hours low, moderate and high exerting activities had been performed the last 7 days.
Measured: 15 minutes at the beginning of each of two test days, which are minimally separated by 5 days between test days.
General Questionnaire
Demographical and physical characteristics were questioned in a self-developed general questionnaire as well as educational/occupational levels, substance and medication use, general physical and mental health at the beginning of test day 1.
Measured: 10 minutes at the beginning of test day 1
General Questionnaire - Short
Only a short part of the General Questionnaire was repeated at the start of test day two. Demographic, physical and educational/occupational information would not alter between 2 test days, so these sections were unnecessary to question again at test day 2. Therefore a shorter version with only questions about substance and medication use since the previous test day, general physical and mental health was administered on test day 2.
Measured: 10 minutes at the beginning of test day 2
Hospital Anxiety and Depression Scale (HADS)
The HADS was administered before each test day in order to be able to assess feelings of anxiety and depression experienced during the last week. This without including physical aspects, but solely the mental aspects thereof. 14 items (7 for anxiety, 7 for depression) had to be answered on a 4-point Likert scale (0-3). A total score would then be calculated ranging from 0-7 (no depression/anxiety), over 8-10 (possible depression/anxiety), to 11-21 (likely depression/anxiety).
Measured: 7 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Pain Catastrophizing Scale (PCS)
The PCS is a self-assessment scale that gives a valid indication of the amount of catastrophizing in both clinical and non-clinical populations. Catastrophizing plays an important role in the experience and consequent handling of pain. 13 statements have to be scored on a 5-point scale ranging from 0 ('not at all applicable') to 4 ('always applicable'). Total scores (0-52) as well as subscales for rumination (4 items), magnification (3 items) and helplessness (6 items) can be calculated.
Measured: 7 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Tampa Scale for Kinesiophobia (TSK)
The TSK is a questionnaire that assesses pain-related fear during everyday movements, and is mostly used for CLBP and fibromyalgia patient groups. It consists out of 17 items that can be subdivided into pathological somatic focus (5 items) and activity avoidance (8 items) questions. All statements have to be scored on a 4-point score, ranging from 1 ('strongly disagree') to 4 ('strongly agree'). A total score is calculated after inversion of the individual scores of items 4, 8, 12 and 16. A total score, and subscores for pathological somatic focus (5-20), and activity avoidance (8-32) can be calculated.
Measured: 8 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Pain Vigilance and Awareness Questionnaire (PVAQ)
The PVAQ is a broad measure of attention to pain, which can be applied to various pain populations. It consists of 16 statements, and respondents have to indicate on a 6-point scale (0 = never, 6 = always) the extent to which these statements correspond to their behaviour in the last week.
Measured: 8 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Roland Morris Disability Questionnaire (RMDQ)
The RMDQ specifically measures the physical condition of people with low back pain complaints and the manner in which this interferes with daily activities. It consists out of 24 questions about activities that might be disturbed by LBP. Respondents have to answer 'yes' or 'no' on each question to, leading to a total score (0-24) that reflects the amount of disability experienced.
Measured: 10 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Central Sensitization Inventory (CSI)
The CSI is a questionnaire that assesses to which extent several central sensitization related aspects are present in the respondents. Therefore, respondents are required to score 25 statements on a 5-point Likert scale ranging from 0 ('never') to 4 ('always'). Furthermore, previous diagnostics of 10 sensitization-related syndromes (like fibromyalgia) are also assessed. Total scores on the CSI are divided subclinical (0-29), mild (30-39), moderate (40-49), severe (50-59), and extreme (60-100) regarding presence of central sensitization aspects.
Measured: 10 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2018
- Study start3 Mar 2017
- Primary completion17 Apr 2018
- Study completion17 Apr 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Low Back PainStudies of the same condition, open and under way.
- More trials run by University GhentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Each participant will perform both experimental conditions spread out over 2 test days in a randomized order. Between 2 test days a minimum of 5 days has to be present in order to ensure full recuperation from test day 1. Half of the participants will receive the control condition on test day 1 and the fear condition on day 2, the other half vice versa.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 107 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Ghent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lieven Danneels, PT, PhD, Principal investigator, University Ghent
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03705676
- Sponsor's protocol ID
- 2016/0186
- Status last verified
- Dec 2023
- First submitted
- 5 Sep 2018
- Last updated
- 18 Dec 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No individual participant data will be shared after completion of the study.
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Unraveling the Puzzle of Back Pain Chronicity: an Integrative Perspective on Sensorimotor Control and Maladaptive Cognitive Processes
- ClinicalTrials.gov ID
- NCT03705676
- Acronym / sponsor ID
- 2016/0186
- Conditions
- Low Back Pain
- Keywords
- Sensorimotor control, Event-related potentials, Cortical movement preparation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 107 participants (actual)
- Lead sponsor
- University GhentUniversity, hospital or other
- Study start
- 3 Mar 2017 (actual)
- Primary completion
- 17 Apr 2018 (actual)
- Study completion
- 17 Apr 2018 (actual)
- First posted
- 15 Oct 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims at examining the influence of both threat of experimentally induced pain and clinical low back pain (LBP) on trunk motor control on the one hand and brain activity related to movement preparation on the other hand. Therefore, 3 groups are studied: healthy controls, people with recurrent LBP, and people with chronic LBP. A comparison in electromyography (EMG) of the trunk muscles and electroencephalography (EEG) activity between the 3 groups will be made in 2 conditions: a control condition without experimental pain on 1 test day, and a fear condition with experimental pain on another test day. In both conditions a motor control task will be performed and muscle and brain activity will be measured during each motor control task.
It is hypothesised that motor control will be different between the 3 groups in both conditions, i.e. delayed trunk muscle onset in LBP groups compared with controls. With regards to the brain activity, it is expected that preparation for movement will also be delayed in the LBP groups. Furthermore, it is expected that the fear condition will entail differences in both EMG and EEG within each group.
Detailed description
March 2017 - April 2018. 30 healthy participants, 30 recurrent and 30 chronic LBP patients all aged 18-45 and of both genders were tested for 2 conditions on 2 separate days, i.e. a control condition (C) on 1 test day; a fear (F) condition consisting out of threat (T) and no threat trials (NT) on another test day. The order of test days was randomized.
1 block of 240 rapid arm movements (RAM) with the dominant arm was performed per condition, while electroencephalography (EEG) of the brain and surface electromyography (sEMG) of the Internal Oblique/Transversus Abdominis, External Oblique, Multifidus and Iliocostalis Lumborum pars Thoracis muscles were measured bilaterally. sEMG of the Anterior Deltoid muscle of the dominant arm was also measured. This RAM was used to induce an internal perturbation to the postural balance of subjects and is an often used task in the study of trunk motor control. Midway the RAM block, the participants got a short intermission of 90 seconds seated rest. Both conditions consisted of a warning cue (colored dot on a screen) followed by a go cue (arrow indicating either an upwards or downwards rapid arm movement) or a no-go cue ('STOP') and 12 seconds rest before the next trial. Harmless vibrotactile stimuli were always administered to the low back region during the appearance of the warning cue. During the C, a white warning cue was presented (safe cue), meaning that the RAM would never be accompanied by a painful electrocutaneous stimulus in that condition. During the F a safe (no threat) or a threatening warning cue could be presented (50-50%); in 25% of the trials after the threatening cue an electrocutaneous stimulus was given to the lower back region; the trials after the no threat cue were never accompanied with painful stimuli.
The intensity of the electrocutaneous stimulus was self-determined by participants through a staircase paradigm and was administered by a digitimer system.
At the beginning of each test day several questionnaires were also administered to control for psychological factors and physical activity, i.e. Central Sensitization Index (CSI), Hospital Anxiety and Depression Scale (HADS), Tampa Scale for Kinesiophobia (TSK), Pain Catastrophizing Scale (PCS), Pain Vigilance and Awareness Questionnaire (PVAQ), Roland-Morris Disability Questionnaire (RMDQ), International Physical Activity Questionnaire (IPAQ) and a general questionnaire regarding socio-demographic information and history of complaints. Furthermore, complaint specific questionnaires were also administered, but only for the clinical populations (RLBP and CLBP)
Statistical analysis will be performed to assess whether and to what extent both threat and LBP might influence motor control as measured with EMG during RAM. Furthermore, the effect of both on cortical movement preparation and somatosensory processing will also be assessed based on the EEG measurements.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 6
- Model description
- Each participant will perform both experimental conditions spread out over 2 test days in a randomized order. Between 2 test days a minimum of 5 days has to be present in order to ensure full recuperation from test day 1. Half of the participants will receive the control condition on test day 1 and the fear condition on day 2, the other half vice versa.
| Arm | Type | Receives |
|---|---|---|
| Healthy controls - control condition | Active comparator | Behavioral: Rapid Arm Movements, Device: Vibrotactile stimulusAssesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli. |
| Healthy controls - fear condition | Experimental | Behavioral: Rapid Arm Movements, Device: Unpleasant stimulus, Device: Vibrotactile stimulusAssesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials. |
| RLBP - control condition | Active comparator | Behavioral: Rapid Arm Movements, Device: Vibrotactile stimulusAssesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli. |
| RLBP - fear condition | Experimental | Behavioral: Rapid Arm Movements, Device: Unpleasant stimulus, Device: Vibrotactile stimulusAssesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials. |
| CLBP - control condition | Active comparator | Behavioral: Rapid Arm Movements, Device: Vibrotactile stimulusAssesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli. |
| CLBP - fear condition | Experimental | Behavioral: Rapid Arm Movements, Device: Unpleasant stimulus, Device: Vibrotactile stimulusAssesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Healthy adult subjects.
- People with non-specific recurrent LBP for at least 2 episodes last year. (1 episode = >24h complaints; 2 episodes are separated by a painfree period of at least 1 month)
- People with non-specific chronic LBP for at least 3 days a week and this for at least 3 months on a row.
Key exclusion criteria (62 listed)
- People with a history of pain or current pain
- severe pathologies
- traumata
- cardiorespiratory disorders
- neurological disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rapid Arm Movements240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction. | Behavioural | CLBP - control condition, CLBP - fear condition, Healthy controls - control condition, Healthy controls - fear condition, RLBP - control condition, RLBP - fear condition |
| Unpleasant stimulusAlso: Electrocutaneous stimulusAn unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization). | Device | CLBP - fear condition, Healthy controls - fear condition, RLBP - fear condition |
| Vibrotactile stimulusIn all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase. | Device | CLBP - control condition, CLBP - fear condition, Healthy controls - control condition, Healthy controls - fear condition, RLBP - control condition, RLBP - fear condition |
Primary outcome
Trunk muscle EMG latency
Time frame: 2 hours
Latency of the activation onset of the trunk muscles on EMG compared to prime mover onset (Anterior Deltoid) in milliseconds.
Contingent Negative Variation
Time frame: 2 hours
A cortical EEG-potential that reflects movement preparation in the timeframe between a warning cue and a go cue in Volt.
Somatosensory Evoked Potentials
Time frame: 2 hours
Cortical EEG-potentials that reflect the awareness and processing of somatosensory information, in this case vibrotactile stimuli on the lower back in Herz.
11 secondary outcomes
Visual Analogue Scale for Pain
Time frame: Before, midway and after each RAM block, with a duration of 10 seconds. This in both test day 1 and 2, which are minimally separated by 5 days between test days.
Rating of Perceived Exertion/Borg
Time frame: After each RAM block, with a duration of 5 seconds. This in both test day 1 and 2, which are minimally separated by 5 days between test days.
International Physical Activities Questionnaire
Time frame: 15 minutes at the beginning of each of two test days, which are minimally separated by 5 days between test days.
General Questionnaire
Time frame: 10 minutes at the beginning of test day 1
General Questionnaire - Short
Time frame: 10 minutes at the beginning of test day 2
Hospital Anxiety and Depression Scale (HADS)
Time frame: 7 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Pain Catastrophizing Scale (PCS)
Time frame: 7 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Tampa Scale for Kinesiophobia (TSK)
Time frame: 8 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Pain Vigilance and Awareness Questionnaire (PVAQ)
Time frame: 8 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Roland Morris Disability Questionnaire (RMDQ)
Time frame: 10 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Central Sensitization Inventory (CSI)
Time frame: 10 minutes at the beginning of test day 1 and 2, which are minimally separated by 5 days between test days.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2023.
- Individual participant dataSharing planned: No. No individual participant data will be shared after completion of the study.
Related trials for Low Back Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Not yet recruiting
Effect of Lumbar Stabilization Exercises With and Without YTWL (Scapular Stabilization Exercises) on Reducing Chronic Low Back Pain and Related Disability. A Randomized Clinical Trial,
Chronic Non Specific Mechanical Low Back Pain
Not yet recruiting
Comparing Non-Medicine Strategies for Improving Low Back Pain
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Not yet recruiting
Effects of Whole-Body Vibration and Cervical Stabilization With Core Stabilization in Young Adults With Non-Specific Low Back Pain
Nonspecific Low Back Pain
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lieven Danneels, PT, PhD principal investigator
University Ghent
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rapid Arm Movements, Unpleasant stimulus and Vibrotactile stimulus in people with Low Back Pain, run by University Ghent at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 62 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Trunk muscle EMG latency (time frame: 2 hours). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2023.